Therapeutic Drug Monitoring of Antiretrovirals

Mark A Marzinke

doi:10.1016/B978-0-12-802025-8.00006-4

Therapeutic Drug Monitoring of Antiretrovirals

Mark A Marzinke

School of Medicine

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Antiretroviral therapy (ART) is a primary modality for the treatment and management of HIV/AIDS. Antiretroviral (ARV) agents are associated with drug-drug interactions and high inter-individual variability. The current status of therapeutic drug monitoring (TDM) for ARV drug classes will be discussed. Additionally, first-line study regimens, consensus recommendations, and analytical methodologies will also be included in this chapter.

Original language	English (US)
Title of host publication	Clinical Challenges in Therapeutic Drug Monitoring: Special Populations, Physiological Conditions, and Pharmacogenomics
Publisher	Elsevier Inc.
Pages	135-163
Number of pages	29
ISBN (Electronic)	9780128020524
ISBN (Print)	9780128020258
DOIs	https://doi.org/10.1016/B978-0-12-802025-8.00006-4
Publication status	Published - May 17 2016

Fingerprint

Keywords

Antiretrovirals
HAART therapy
Limitations
Protease inhibitors
Therapeutic drug monitoring

ASJC Scopus subject areas

Medicine(all)

Cite this

Marzinke, M. A. (2016). Therapeutic Drug Monitoring of Antiretrovirals. In Clinical Challenges in Therapeutic Drug Monitoring: Special Populations, Physiological Conditions, and Pharmacogenomics (pp. 135-163). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-802025-8.00006-4

@inbook{3b9f1d5be48d46b3adc87e0344e5cd70,

title = "Therapeutic Drug Monitoring of Antiretrovirals",

abstract = "Antiretroviral therapy (ART) is a primary modality for the treatment and management of HIV/AIDS. Antiretroviral (ARV) agents are associated with drug-drug interactions and high inter-individual variability. The current status of therapeutic drug monitoring (TDM) for ARV drug classes will be discussed. Additionally, first-line study regimens, consensus recommendations, and analytical methodologies will also be included in this chapter.",

keywords = "Antiretrovirals, HAART therapy, Limitations, Protease inhibitors, Therapeutic drug monitoring",

author = "Marzinke, {Mark A}",

year = "2016",

month = "5",

day = "17",

doi = "10.1016/B978-0-12-802025-8.00006-4",

language = "English (US)",

isbn = "9780128020258",

pages = "135--163",

booktitle = "Clinical Challenges in Therapeutic Drug Monitoring: Special Populations, Physiological Conditions, and Pharmacogenomics",

publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Therapeutic Drug Monitoring of Antiretrovirals

AU - Marzinke, Mark A

PY - 2016/5/17

Y1 - 2016/5/17

N2 - Antiretroviral therapy (ART) is a primary modality for the treatment and management of HIV/AIDS. Antiretroviral (ARV) agents are associated with drug-drug interactions and high inter-individual variability. The current status of therapeutic drug monitoring (TDM) for ARV drug classes will be discussed. Additionally, first-line study regimens, consensus recommendations, and analytical methodologies will also be included in this chapter.

AB - Antiretroviral therapy (ART) is a primary modality for the treatment and management of HIV/AIDS. Antiretroviral (ARV) agents are associated with drug-drug interactions and high inter-individual variability. The current status of therapeutic drug monitoring (TDM) for ARV drug classes will be discussed. Additionally, first-line study regimens, consensus recommendations, and analytical methodologies will also be included in this chapter.

KW - Antiretrovirals

KW - HAART therapy

KW - Limitations

KW - Protease inhibitors

KW - Therapeutic drug monitoring

UR - http://www.scopus.com/inward/record.url?scp=85011774845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011774845&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-802025-8.00006-4

DO - 10.1016/B978-0-12-802025-8.00006-4

M3 - Chapter

AN - SCOPUS:85011774845

SN - 9780128020258

SP - 135

EP - 163

BT - Clinical Challenges in Therapeutic Drug Monitoring: Special Populations, Physiological Conditions, and Pharmacogenomics

PB - Elsevier Inc.

ER -

Access to Document

10.1016/B978-0-12-802025-8.00006-4